An Open Phase I/II Clinical Study Assessing the Safety and Tolerability of APO866 in Patients With Refractory B-cell Lymphocytic Leukaemia Not Amenable to Allogeneic Hemopoietic Stem Cell Transplantation

Trial Profile

An Open Phase I/II Clinical Study Assessing the Safety and Tolerability of APO866 in Patients With Refractory B-cell Lymphocytic Leukaemia Not Amenable to Allogeneic Hemopoietic Stem Cell Transplantation

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Daporinad (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Sponsors Onxeo SA; TopoTarget Switzerland
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Mar 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top